FACTBOX-Top investors at biotech targets1 hour ago by Thomson Reuters May 2 (Reuters) - Biotech companies are being targeted by large drugmakers seeking new products to rejuvenate their product pipelines. The table below shows the three largest investors at leading takeover targets and the aggregate holdings of the top 10 investors: 1st 2nd 3rd Top 10 Amylin Fidelity Wellington Icahn 56 pct Alexion Fidelity T.Rowe Price Capital Res. 51 pct Biomarin Capital Res. Fidelity PRIMECAP 58 pct Exelixis Fidelity T.Rowe Price Wellington 55 pct Human Genome Loomis T.Rowe Price Fidelity 78 pct Illumina Capital Res. Baillie Giff. Sands 66 pct Onyx Wellington BlackRock Samana 48 pct Regeneron Sanofi Capital World Fidelity 75 pct Seattle Gen. Baker Bros. Fidelity Wellington 80 pct Vertex Fidelity Capital World Janus 46 pct Source: U.S. Securities and Exchange Commission filings (Reporting by Paritosh Bansal and Ben Hirschler) .